Results 111 to 120 of about 40,356 (246)

Cardiometabolic Treatment Gap in Routine Psychiatric Care: A Cross‐Sectional Study of 1553 Patients

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background People with severe mental illness (SMI) have elevated cardiometabolic morbidity and mortality, with similar concerns increasingly reported in other psychiatric conditions including anxiety disorders and ADHD. Somatic conditions are often underdiagnosed and pharmacologically undermanaged in this population.
Vincent Achour, Melanie Faugere, Laurent Boyer, Christophe Lançon, Theo Korchia   +4 more
wiley   +1 more source

The Construct of Medical and Non-Medical Marijuana-Critical Review. [PDF]

Int J Environ Res Public Health, 2022
Silczuk A, Smułek D, Kołodziej M, Gujska J.   +3 more
europepmc   +1 more source

Daily or near‐daily cannabis and alcohol use by adults in the United States: A comparison across age groups

Addiction, Volume 120, Issue 4, Page 779-782, April 2025.
Abstract Background and aims Patterns of daily or near‐daily (DND) use of alcohol and cannabis among adults in the United States have been changing. The current study measured how these shifts have occurred across developmental periods of adulthood. Design, Setting, and Participants U.S.
Megan E. Patrick
wiley   +1 more source

Medical marijuana.

The Western journal of medicine, 1998
Although many clinical studies suggest the medical utility of marijuana for some conditions, the scientific evidence is weak. Many patients in California are self-medicating with marijuana, and physicians need data to assess the risks and benefits. The only reasonable solution to this problem is to encourage research on the medical effects of marijuana.
openaire   +3 more sources

Observational study of medical marijuana as a treatment for treatment-resistant epilepsies. [PDF]

Ann Clin Transl Neurol, 2022
Devinsky O, Marmanillo A, Hamlin T, Wilken P, Ryan D, Anderson C, Friedman D, Todd G.   +7 more
europepmc   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Medical marijuana knowledge and attitudes amongst internal medicine residents. [PDF]

BMC Prim Care, 2022
Makki I, Zheng-Lin B, Kohli M.
europepmc   +1 more source

Association of fully branded, standardized packaging and limited flavor and brand descriptors of e‐liquids with interest in trying products among youths in Great Britain

Addiction, Volume 120, Issue 4, Page 620-628, April 2025.
Abstract Background and aims Many vaping products feature bright colors and novel brand names and flavor descriptors, which may appeal to youth. We measured the strength of the associations between e‐liquid packaging design (branded, white standardized or white standardized limiting brand and flavor descriptors) and perceived peer interest in trying ...
Eve Taylor, Erikas Simonavičius, Matilda Nottage, Ann McNeill, Deborah Arnott, Hazel Cheeseman, David Hammond, Jessica Reid, Pete Driezen, Kimberly D'Mello, Katherine East   +10 more
wiley   +1 more source

Examining the role of freebase nicotine in the harm reduction potential of oral nicotine pouches versus moist snuff: A randomized crossover trial

Addiction, EarlyView.
Abstract Background and aims Oral nicotine pouches (ONPs) contain varying proportions of freebase nicotine (FBN), with higher FBN expected to increase nicotine delivery across the oral mucosa. Because ONPs contain fewer toxicants than moist snuff and may serve as a reduced harm alternative for smokeless tobacco, we compared how the FBN in ONPs affects ...
Brittney Keller‐Hamilton, Hayley Curran, Leanne Atkinson, Sriya Suraapaneni, Alice Hinton, Kirsten Chrzan, Darren Mays, Ahmad El‐Hellani, Clark W. Wilson, Marielle C. Brinkman, Theodore L. Wagener   +10 more
wiley   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source